Stock RLAY RELAY THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Relay Therapeutics, Inc.

Equities

RLAY

US75943R1023

Market Closed - Nasdaq
Other stock markets
 04:00:04 2024-04-23 pm EDT 		5-day change 1st Jan Change
5.89 USD -1.01% Intraday chart for Relay Therapeutics, Inc. -5.15% -46.50%
Mar. 12 Transcript : Relay Therapeutics, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 07:30 AM
Feb. 23 Relay Therapeutics Q4 Loss Widens, Reports No Revenue MT

Strengths

  • For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
  • Analysts remain confident with respect to the group's activity and, more often than not, have revised upwards their earnings per share estimates.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • The company's profitability before interest, taxes, depreciation and amortization characterizes fragile margins.
  • Low profitability weakens the company.
  • The company is in a hindered financial situation with significant debt and rather low EBITDA levels.
  • Based on current prices, the company has particularly high valuation levels.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
RELAY THERAPEUTICS, INC. Stock Relay Therapeutics, Inc.
-46.50% 781M
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+3.13% 42.11B
B
LONZA GROUP AG Stock Lonza Group AG
+48.83% 40.08B
A
MODERNA, INC. Stock Moderna, Inc.
+8.49% 40B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-10.82% 26.87B
C
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.26% 24.58B
B-
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-23.69% 18.44B
B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
+1.58% 11.94B
C+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+32.83% 11.66B
C+
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.63% 11.01B
B+
Investor Rating
Trading Rating
ESG Refinitiv

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
-
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Environment

Emissions
Innovation
Use of resources

Social

Social commitment
Human Rights
Product liability
Human Resources

Governance

CSR Strategy
Management
Shareholders

Controversy

Controversy

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. RLAY Stock
  4. Ratings Relay Therapeutics, Inc.